Alamar Biosciences, Inc. (ALMR) Stock Price & How to Invest

Last updated November 2026

Short answer

ALMR is Alamar Biosciences, a Fremont, California proteomics company that listed on Nasdaq in April 2026, and it trades like any other US stock at any broker, in whole or fractional shares. It sells one instrument, the ARGO HT, and the NULISA assay panels that run on it, so the number that actually drives the business is how much consumable revenue each placed machine pulls through in a year. As of October 16, 2026 the shares closed near $25.60, a market cap of about $1.8 billion, well below the August peak but still above the $17 IPO price.

ALMR stock price

As of 2026-11-16, Alamar Biosciences, Inc. (ALMR) last closed at $30.55, up 20.8% over the past month. Over its trading history so far it has traded between $19.09 and $38.13.

ALMR last close
$30.55
1 day
-0.84%
1 month
+20.85%
1 year
n/a
Range since listing
$19.09 to $38.13
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Alamar Biosciences, Inc.'s investor relations page. Walnut is informational, not investment advice.

ALMR key stats

At $30.55 on November 16, 2026, Alamar Biosciences, Inc. (ALMR) has a market cap of $2.1B.

Market cap
$2.1B
Price to book
7.0

Market cap, P/E and yield are measured at the $30.55 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Alamar Biosciences, Inc. (ALMR)?

The last two weeks for Alamar Biosciences, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • ALMR closed at $30.55 on November 16, 2026, down 4.1% over the past five trading days (from $31.84).
  • On November 4, 2026, Alamar Biosciences, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 3, 2026, Alamar Biosciences, Inc. filed an 8-K with the SEC reporting quarterly results and a change in its directors or officers (Item 2.02, Item 5.02). Read the 8-K on sec.gov
  • On November 4, 2026, TD Cowen raised its target to $36.00 from $34.00 (Buy).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Alamar Biosciences, Inc. (ALMR) do?

Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Its core technology, NULISA, pairs antibody capture with a sequencing readout to push sensitivity far below standard ELISA methods, and the ARGO HT system, launched commercially in January 2024, automates the workflow so a lab can run hundreds of samples across a multiplexed panel. The panels are where the recurring money is: NULISAseq Neuro 220 for neurodegeneration work, Inflammation 250, and the newer Immune 340 for translational immunology, plus an eMTBR-tau blood bioassay added to the neuro panel in 2026. Customers are academic labs, biotechs and pharma research groups, more than 300 of them across 25 countries, and the company was founded in 2018 by Yuling Luo, who previously built Advanced Cell Diagnostics.

The model is instruments first, consumables after, and the second quarter of 2026 showed that mix working. Revenue reached $29.4 million, up 82% year over year, but the split matters more than the total: instrument sales grew 35% to $7.8 million while consumables grew 147% to $15.5 million, which is what a maturing installed base is supposed to look like. Gross margin widened to 60% from 53%. The company is still spending ahead of that, with $31.2 million of operating expenses producing a $13.2 million quarterly net loss, funded by roughly $250 million of cash and short-term investments left over from the April IPO at $17 a share. Management guided full-year 2026 revenue to $116 million to $120 million, about 59% growth at the midpoint, and the stock rose roughly 31% on August 11, 2026 in response to the results and that first public guidance. That rally did not hold. The shares peaked at $39.61 and closed at $25.60 on October 16, 2026, down about 27% over the past month, though still about 16% above where they first traded and well above the $17 offer. At that price the market cap is about $1.8 billion, roughly 18 times trailing revenue of about $100 million, or around 13 times guided 2026 revenue net of cash. In October the company added former Grail CEO Bob Ragusa to its board and expanded its leadership team, and it reports third-quarter results on November 3, 2026, where consensus expects revenue of about $30.2 million and a loss of about $0.19 a share.

What's driving Alamar Biosciences, Inc. (ALMR)?

1. Consumable pull-through per instrument

Alamar reported average annual pull-through above $400,000 per instrument for 2025, and consumables grew 147% in the second quarter of 2026 against 35% instrument growth. That gap is the whole economic argument for the platform: once an ARGO HT is installed, revenue should recur without another capital sale. Watch whether pull-through holds above the $400,000 mark as newer, less established installs dilute the average.

2. Installed base expansion

The cumulative installed base passed 100 instruments by the end of 2025, spread across more than 300 customers in 25 countries, and management has pointed to a similar pace of placements through 2026. Each placement is a small annuity, so the count compounds into the consumable line with a lag of a few quarters. International expansion is part of this, including the first APAC install at a Hong Kong neurodegenerative disease center.

3. Neurodegeneration research demand

Blood-based protein markers for Alzheimer's and related conditions have become one of the busiest areas in translational research, and the Neuro 220 panel plus the eMTBR-tau assay put Alamar directly in front of that spending. Concentration in one field cuts both ways, so the Immune 340 panel launch is the attempt to widen the base into immunology and oncology work. How quickly non-neuro panels contribute is a reasonable proxy for whether this becomes a platform or stays a niche. A September 2026 Lancet Neurology study used Alamar's technology to show divergent biological responses to Alzheimer's treatment, the kind of published clinical-research use that tends to pull in more panel orders.

4. Margin leverage against the loss

Gross margin moved from 53% to 60% in a year as consumables took a larger share of the mix, which is the normal pattern for this kind of business. Operating expenses rose 89% over the same period, to $31.2 million, so the loss has not narrowed yet. Q2 net loss per share of about $0.20 did beat the roughly $0.32 consensus, and analysts expect a loss near $1.10 a share for 2026 narrowing to about $0.45 in 2027 on revenue of roughly $166 million. With about $250 million of cash on hand the runway is comfortable, and the question is whether revenue growth outruns the spending curve before that cushion becomes a topic.

What are the risks to Alamar Biosciences, Inc. (ALMR)?

Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Competition is well capitalized: Olink sits inside Thermo Fisher, SomaScan inside Standard BioTools, and Quanterix, Bio-Techne and the mass-spectrometry vendors all sell into the same labs, which means sensitivity and cost per sample claims get tested constantly. The panels are sold for research rather than clinical diagnosis, so any move toward diagnostics would bring regulatory work and cost that is not in today's numbers. Valuation still leaves little slack, with the shares near 18 times trailing revenue while the company loses money each quarter, and the 27% fall over the past month shows how hard a small, recently listed stock can reprice without any change in reported numbers. The IPO was in April 2026 and typical lockup arrangements expire around six months after listing, which falls in mid-October 2026 and can put additional shares into a thinly traded float. The November 3 third-quarter report is the next test of the $116 million to $120 million full-year guide.

What is the Alamar Biosciences, Inc. (ALMR) forecast?

5 analysts publish price targets on ALMR, averaging $37.00 as of November 2026, or +21.1% against the $30.55 share price on November 16, 2026. The published targets run from $34.00 to $45.00, a narrow spread, and the ratings split 4 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ALMR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is ALMR a buy or a sell?

We give no verdict on Alamar Biosciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Consumable pull-through per instrument. Alamar reported average annual pull-through above $400,000 per instrument for 2025, and consumables grew 147% in the second quarter of 2026 against 35% instrument growth. The most optimistic published target, $45.00, assumes this works close to its best case.

The case against. Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. The most pessimistic target, $34.00, is roughly what ALMR is worth if this bites instead.

Read the full bull and bear case on ALMR, including what would have to change to break either one. Walnut is not an investment adviser.

Has Alamar Biosciences, Inc. (ALMR) split its stock?

No. Alamar Biosciences, Inc. (ALMR) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Alamar Biosciences, Inc. (ALMR) valued?

Market cap, P/E and dividend yield at today's price are in the ALMR key stats above. The business figures below come from Alamar Biosciences, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year
  • 2026 revenue guidance: ~$116 million to $120 million (consensus ~$119 million)
  • Gross margin (TTM): ~59% (Q2 2026 ~60%)
  • Net loss (TTM): ~$50 million; Q2 2026 EPS ~-$0.20 vs ~-$0.32 expected
  • Cash / debt: ~$250 million / ~$51 million at June 30, 2026

As of October 2026: There is no meaningful price to earnings ratio because the company loses money, so the market works off revenue multiples: about 18 times trailing sales, or roughly 13 times the 2026 guide once net cash is taken out, down from above 20 times in August. That is still a premium tools multiple for a platform growing north of 50% with widening gross margin. Five analysts carry a mean target near $35.40, and the November 3 report will show whether third-quarter revenue lands near the roughly $30.2 million consensus.

Who competes with Alamar Biosciences, Inc. (ALMR)?

Multiplex affinity proteomics platforms

Olink, now owned by Thermo Fisher, and the SomaScan platform inside Standard BioTools are the direct rivals for the same panel-based protein profiling work, with Quanterix competing on the ultra-sensitive single-molecule side. These platforms are compared on sensitivity, how many proteins run per sample, sample volume required and cost per data point, and labs frequently benchmark two or three against each other before committing to consumables.

Mass-spectrometry proteomics

Thermo Fisher's Orbitrap instruments, Bruker's timsTOF line and Seer's Proteograph take the unbiased discovery route rather than a fixed antibody panel. They compete for the same research dollar and the same bench space, and the trade is breadth of proteins detected against the sensitivity and throughput a targeted panel delivers on low-abundance markers in blood.

Established immunoassay suppliers

Bio-Techne, Meso Scale Discovery and the big catalog reagent vendors already hold the purchasing relationships and the shelf space in most labs. They rarely match NULISA on sensitivity, but they are cheap, familiar and validated, which makes them the default a new platform has to displace one customer at a time.

What stocks are similar to Alamar Biosciences, Inc. (ALMR)?

Other names that sit close to ALMR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Alamar Biosciences, Inc. (ALMR)

There are three common ways to get ALMR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALMR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ALMR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Alamar Biosciences, Inc. (ALMR)

Alamar is an early, fast-growing razor-and-blade tools business; after a roughly 27% slide over the past month the shares trade near 18 times trailing sales, and consumable pull-through per instrument is still the figure that has to keep compounding.

More on Alamar Biosciences, Inc. (ALMR)

Whether ALMR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALMR a buy or a sell?, and where the stock could go from here in the ALMR stock forecast.

For income investors, whether ALMR pays a dividend and how the payout looks is covered in does ALMR pay a dividend? And to weigh ALMR against a peer, read the full side-by-side comparisons: ALMR vs BRKR and ALMR vs TECH.

Wondering how ALMR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Alamar Biosciences, Inc.

Ask Walnut's AI anything about ALMR and see how it fits what you own.

FAQ

What does Alamar Biosciences actually do?

+

It sells laboratory instruments and the reagent kits that run on them, aimed at measuring proteins in blood and other biofluids at very low concentrations. The ARGO HT system automates the workflow, and NULISAseq panels such as Neuro 220, Inflammation 250 and Immune 340 are the consumables that generate recurring revenue. Customers are research labs in academia, biotech and pharma, more than 300 of them across 25 countries.

What is NULISA and why does it matter?

+

NULISA is Alamar's assay chemistry, which combines antibody-based protein capture with a sequencing readout instead of the fluorescence or colorimetric detection a conventional immunoassay uses. It is built for sensitivity: it targets proteins that circulate at concentrations standard ELISA methods cannot reliably read, which is what makes blood-based measurement of neurological markers practical. That sensitivity claim is also what competitors attack, so independent benchmarking studies carry weight in this market.

How does a US investor buy ALMR?

+

ALMR trades on the Nasdaq Global Select Market, so any US broker can buy it in dollars during normal market hours, including fractionally at brokers that support fractional orders. It listed on April 17, 2026 after pricing its IPO at $17 a share. Because it is a recent, small-cap listing with a limited float, spreads and daily swings tend to be wider than in a large-cap stock.

Is Alamar Biosciences profitable?

+

No. The company posted a net loss of about $13.2 million in the second quarter of 2026 and about $50 million over the trailing twelve months. Gross margin is healthy at around 60% and rising, so the loss comes from spending on R&D and commercial expansion rather than from the underlying unit economics. Roughly $250 million of cash and short-term investments funds that spending for now, against about $51 million of debt, and there is no dividend.

Why did ALMR stock jump in August 2026?

+

The company reported second-quarter results on August 10, 2026 showing 82% revenue growth to $29.4 million, consumable revenue up 147%, and gross margin expanding to 60%, then issued its first public full-year guidance of $116 million to $120 million. The shares rose roughly 31% on August 11. For a company four months past its IPO, the first guidance number carries unusual weight because there was no prior public track record to anchor expectations.

What is pull-through and why do people watch it for this stock?

+

Pull-through is the annual consumable revenue an installed instrument generates. Alamar reported an average above $400,000 per instrument for 2025 across an installed base that passed 100 units. Instrument sales are lumpy and one-time, so pull-through is the measure of whether machines already in the field are being used heavily, and a decline in it would signal that placements are outpacing real laboratory demand.

Who competes with Alamar Biosciences?

+

The closest rivals are Olink, owned by Thermo Fisher, and the SomaScan platform inside Standard BioTools, with Quanterix competing on ultra-sensitive detection. Mass-spectrometry vendors including Thermo Fisher, Bruker and Seer compete for the same research budgets with a different approach, and incumbent immunoassay suppliers such as Bio-Techne and Meso Scale Discovery hold the existing lab relationships. Each of these is larger than Alamar and several are attached to a full catalog business.

What are the main things to watch from here?

+

Three items: whether pull-through per instrument stays above roughly $400,000 as newer installs mature, whether non-neurology panels start contributing enough to reduce dependence on Alzheimer's research spending, and whether the gap between revenue growth and operating expense growth begins to close. The IPO lockup on insider shares typically expires around six months after an April listing, which can add supply to a small float. Research funding conditions in academia and biotech sit underneath all of it. The nearest dated checkpoint is the third-quarter report on November 3, 2026.

How has ALMR stock performed since its IPO?

+

As of the October 16, 2026 close near $25.60, ALMR was about 16% above where it first traded in April and about 51% above the $17 IPO price. It has been volatile: the shares hit a 52-week high of $39.61 after the August earnings jump, then fell about 27% over the past month. The 52-week low is $18.85.

When does Alamar Biosciences report next?

+

Alamar reports third-quarter 2026 results on November 3, 2026. Consensus expects revenue of about $30.2 million and a loss of about $0.19 per share, against Q2 revenue of $29.4 million and a $0.20 loss. Walnut is not an investment adviser and does not tell you whether to buy or sell ALMR.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Alamar Biosciences, Inc.'s investor relations page or your broker before making investment decisions.